HMGA1P2: A Drug Target / Disease Biomarker (G171559)

Target Name: HMGA1P2

NCBI ID: G171559

HMGA1P2

Other Name(s): High mobility group AT-hook 1 pseudogene 2 | HMGA1L2 | high mobility group AT-hook 1 pseudogene 2 | HMGIYL2

HMGA1P2: A Drug Target / Disease Biomarker

HMGA1P2, also known as SLC30A8, is a gene that encodes a protein known as HMGA1P2. The protein is a key regulator of cell-cell adhesion and has been linked to a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a drug target, HMGA1P2 is a promising target for researchers to develop new treatments for a variety of diseases.

HMGA1P2 is a transmembrane protein that is expressed in a variety of tissues throughout the body. It plays a role in the development and maintenance of cell-cell adhesion, which is the process by which cells stick together to form tissues and organs. This process is critical for many biological processes, including embryonic development, tissue repair, and cancer progression.

One of the most significant functions of HMGA1P2 is its role in the regulation of cell-cell adhesion. This protein helps to ensure that cells stick together in a precise and organized manner, which is essential for the development and maintenance of tissues and organs. It also plays a key role in the regulation of cell-cell adhesion during the embryonic development, by which the cells are able to stick together to form the various organs and tissues that make up an organism.

Another important function of HMGA1P2 is its role in the regulation of cell-cell adhesion during the regulation of cell proliferation. This protein helps to ensure that cells are able to stick together and form new tissues and organs, which is essential for the growth and development of all living organisms. It also plays a key role in the regulation of cell-cell adhesion during the regulation of cell differentiation, by which the cells are able to stick together and form different types of tissues and organs.

In addition to its role in cell-cell adhesion, HMGA1P2 has also been linked to a number of diseases. For example, it has been linked to the development and progression of a variety of cancer, including breast cancer, ovarian cancer, and prostate cancer. It has also been linked to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, HMGA1P2 has been linked to the development and progression of a variety of developmental disorders, including Down syndrome and Fragile X syndrome.

As a drug target, HMGA1P2 is a promising target for researchers to develop new treatments for a variety of diseases. For example, it has been shown to be a potential therapeutic target for breast cancer, by which it can inhibit the growth and spread of cancer cells. It has also been shown to be a potential therapeutic target for neurodegenerative diseases, by which it can slow the progression of these diseases. In addition, HMGA1P2 has been shown to be a potential therapeutic target for a variety of other diseases, including developmental disorders and cancer.

Overall, HMGA1P2 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its functions and to develop new treatments based on its properties.

Protein Name: High Mobility Group AT-hook 1 Pseudogene 2

The "HMGA1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGA1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets